With medicare cost coverage in place all ROSG needs are leadership hospitals
to agree to use the test on all patients with CUP and others will follow the influencial hospitals...Sign U of Texas in Houston; Sloan-Kettering in NYC, Johns Hopkins, Mayo, Brigham and Women's, Mass Gen, Cleveland...any one of them on board would push the acceptance of mirco RNA through the barrier of initial resistance....and the stock through the roof.
MD Anderson and Sloan-Ket make too much money on their own testing services to consider outsourcing to ROSG, so even though they did trials on it to confirm the value micro RNA assays they are not the target for sales; instead ROSG will concentrate on offering the test to doctors who do not have such a fancy leash on their collars, but want top shelf testing for their patients.
While the revenue would not be as significant as that of tests performed in their own lab, might it be possible for Rosetta to license the test to these institutions as a cost savings measure to the multiple test that they must use in CUP cases? Perfoming many tests may well line the pockets of these major institutions with medicare money, and no doubt such considerations are at work in the fiscal models that these institutions work from, but also speed and efficiency of patient treatment ought to have some weight as well.